Elevar Therapeutics Announces ANGEL Trial Podium Presentation at ESMO
September 20, 2019
SALT LAKE CITY, USA. Elevar Therapeutics announced that data from the ANGEL trial has been accepted for a podium presentation by the European Society for Professional Oncology at the annual meeting in Barcelona, Spain. The ANGEL trial is a randomized phase 3 study of rivoceranib (commonly known as apatinib) plus best supportive care in gastric cancer patients who had failed at least 2 prior lines of therapy. This presentation will be the first public disclosure of ANGEL study data since the announcement of the topline results in June.
“The ANGEL study represents the first large study of rivoceranib in a global patient population,” said Steven Norton PhD, MBA, Vice President Clinical Development at Elevar Therapeutics. “We appreciate the opportunity for rivoceranib data to be presented at ESMO 2019 and to be able to gather insights from leading oncologists globally during the conference.”
ANGEL Trial Podium Presentation at ESMO
- September 29, 2019 at 11:00 am CET
- Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed 2 prior chemotherapy regimens (ID 4088)
- Location: Fira Barcelona Convention Centre, Madrid Auditorium (Hall 2)
- Presenters:
Yoon-Koo Kang, MD, PhD, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Medical Degree: Seoul National University and PhD: Seoul National University. Before joining the Asan Medical Center, Dr. Kang finished a research fellowship at the National Cancer Institute at NIH, USA and led the clinical program of hematology/oncology and the Laboratory of Experimental Therapeutics at the Korea Cancer Center Hospital in Seoul.
Min-Hee Ryu, MD, University of Ulsan Master of Medicine: Seoul National University Bachelor of Medicine: Seoul National University Major Professional Experiences Associate Professor in Oncology, UUCM AMC Assistant Professor in Oncology, UUCM AMC Fellowship in HematoOncology, UUCM AMC Residency in Seoul National University Hospital Internship in Seoul National University Hospital
ESMO is a leading professional organization for medical oncology, with over 20,000 members from over 150 countries worldwide.
Elevar Therapeutics will be exhibiting at booth #229 during the exhibit hours from September 27-30 at the Fira Barcelona Convention Centre, Hall 3.
About Rivoceranib (Apatinib)
Rivoceranib is the first successful small-molecule angiogenesis inhibitor in gastric cancer. Rivoceranib acts by inhibiting angiogenesis, a critical process in cancer growth and proliferation. Specifically, rivoceranib selectively inhibits VEGFR-2 which mediates the primary pathway for tumor-mediated angiogenesis. It was approved in China (advanced gastric cancer, Dec 2014) where it is marketed by the Chinese-territory license-holder Jiangsu Hengrui Medicine Co., Ltd. Elevar Therapeutics holds the global rights (ex-China). The Company has completed a global (12 countries including US, Japan, Korea, Italy, Germany, and Russia) Phase 3 clinical trial of rivoceranib in advanced or metastatic gastric cancer patients. Elevar Therapeutics is also developing rivoceranib for the treatment of patients with earlier lines of gastric cancer, colorectal cancer, hepatocellular carcinoma, and adenoid cystic carcinoma. Rivoceranib has been clinically tested in over 1,000 patients worldwide and has demonstrated efficacy in numerous cancers including gastric cancer, CRC, HCC, NSCLC, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors. It has also shown potential to significantly improve clinical outcomes in combination with chemotherapeutics and immunotherapy, as well as for maintenance therapy. Elevar Therapeutics has received notification designating rivoceranib as an orphan medicinal product for the treatment of gastric cancer from the European Commission in the European Union, the US FDA, as well as the MFDS in South Korea.
About Elevar Therapeutics
Elevar Therapeutics (formerly LSK BioPharma) is a privately held biopharmaceutical company with offices in Utah, California, and South Korea. The Company aims to provide patients and their caregivers with exceptional choices for effective and well-tolerated therapies. Elevar Therapeutics’ lead proprietary drug candidate is rivoceranib, a selective VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors. Elevar Therapeutics can be found on the web at www.elevartherapeutics.com.
Contact:
Jenna Choi
jenna.choi@elevartherapeutics.com
